OXB's lentiviral vector
manufacturing technology to support Boehringer Ingelheim's newly
initiated Phase I/II trial of first-in-class gene therapy for
cystic fibrosis
Commencement of LENTICLAIR™ 1 trial,
utilising OXB lentiviral vectors; builds on long term
collaboration with Boehringer Ingelheim
Oxford, UK - 20 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and
gene therapy CDMO, today announces that its proprietary lentiviral
vector manufacturing technology will be used in Boehringer
Ingelheim's
newly initiated LENTICLAIR™ 1 trial.
The Phase I/II study is evaluating BI 3720931, a novel,
first-in-class, inhaled gene therapy for the treatment of cystic
fibrosis (CF).
With three decades of expertise in
viral vector development and manufacturing, OXB will support the
development of this potential treatment for CF, a genetic condition
caused by mutations in the CFTR gene that affects more than 100,000
people worldwide. While CFTR modulators have provided treatment
options for some patients, there remains a significant unmet need
for 10-15% of people with CF due to mutation type or modulator
intolerance.
BI 3720931 is a first-in-class,
inhaled lentiviral vector-based gene therapy designed to address
this need through a novel approach of inserting a functional copy
of the CFTR gene in the DNA of airway epithelial cells.
This trial builds on the successful
collaboration initiated in
August 2018 with Boehringer Ingelheim.
OXB's ongoing role in this programme highlights its reputation as a
trusted CDMO and its commitment to advancing pioneering gene
therapies that address significant unmet needs.
Frank Mathias, Chief Executive Officer of OXB,
said: "We are delighted that
Boehringer Ingelheim is using OXB's proprietary lentiviral vector
manufacturing technology for the clinical development of their CF
gene therapy. This programme has the potential to transform the
lives of patients living with CF and exemplifies OXB's commitment
to supporting cutting-edge cell and gene therapies. We look forward
to playing a key role in its progression."
-Ends-
Enquiries:
OXB:
Sebastien Ribault, Chief Business
Officer - T: +44 (0) 1865 783 000 / E:
partnering@oxb.com
ICR
Healthcare:
T: +44 (0)20 3709 5700 /
E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray /
Davide Salvi
About OXB
OXB (LSE: OXB) is a
global quality and
innovation-led contract development and manufacturing organisation
(CDMO) in cell and gene therapy with a mission to enable its
clients to deliver life-changing therapies to patients around the world.
One of the original pioneers in cell
and gene therapy, OXB has
30 years of experience in
viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing
viral vector development and manufacturing
expertise in lentivirus, adeno-associated virus (AAV), adenovirus
and other viral vector types. OXB's world-class capabilities span
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems,
analytical methods and depth of regulatory
expertise.
OXB offers a vast number of unique
technologies for viral vector manufacturing, including a 4th
generation lentiviral vector system (the TetraVecta™ system), dual plasmid system
for AAV production, suspension and perfusion process using process
enhancers and stable producer and packaging cell lines.
OXB, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has bioprocessing and
manufacturing facilities across Oxfordshire, UK,
Lyon and Strasbourg, France and near Boston, MA, US. Learn more
at www.oxb.com, and follow us on LinkedIn
and YouTube.
About Boehringer Ingelheim
Boehringer Ingelheim is a
biopharmaceutical company active in both human and animal health.
As one of the industry's top investors in Research and Development,
the company focuses on developing innovative therapies in areas of
high unmet medical need. Independent since its
foundation in 1885, Boehringer takes a long-term perspective,
embedding sustainability along the entire value chain. More than
53,500 employees serve over 130 markets to build a healthier, more
sustainable, and equitable tomorrow. Learn more
at https://www.boehringer-ingelheim.com.
